Nanjing Leads Biolabs Co (HKSE:09887) Net Margin %: -25.40% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09887 Nanjing Leads Biolabs Co Ltd HKSE:09887
10 GF Score
Price HK$74.60
! 1 Warning Sign
View Full Analysis

What is Nanjing Leads Biolabs Co Net Margin %?

Nanjing Leads Biolabs Co HKSE:09887 +8.04% 10 Net Margin % is -25.40% as of Dec. 2025. GuruFocus rates HKSE:09887 with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Nanjing Leads Biolabs Co ranks worse than 54.24% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Nanjing Leads Biolabs Co's Net Income for the six months ended in Dec. 2025 was HK$-49.7 Mil. Nanjing Leads Biolabs Co's Revenue for the six months ended in Dec. 2025 was HK$195.8 Mil. Therefore, Nanjing Leads Biolabs Co's net margin for the quarter that ended in Dec. 2025 was -25.40%.

The historical rank and industry rank for Nanjing Leads Biolabs Co's Net Margin % or its related term are showing as below:

HKSE:09887' s Net Margin % Range Over the Past 10 Years
Min: -4086.43   Med: -2102.85   Max: -118.28
Current: -118.28

HKSE:09887's Net Margin % is ranked worse than
54.24% of 944 companies
in the Biotechnology industry
Industry Median: -78.86 vs HKSE:09887: -118.28

Nanjing Leads Biolabs Co  (HKSE:09887) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Nanjing Leads Biolabs Co Net Margin % Related Terms

Nanjing Leads Biolabs Co Net Margin % Historical Data

* Premium members only.

The historical data trend for Nanjing Leads Biolabs Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co Net Margin % Chart

Nanjing Leads Biolabs Co Annual Data
Trend Dec23 Dec24 Dec25
Net Margin %
-4,086.43 0.00 -119.27

Nanjing Leads Biolabs Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % 0.00 0.00 0.00 0.00 -25.40

HKSE:09887 vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, Nanjing Leads Biolabs Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing Leads Biolabs Co Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanjing Leads Biolabs Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nanjing Leads Biolabs Co's Net Margin % falls into.


HKSE:09887
10GF Score
Nanjing Leads Biolabs Co Ltd HKSE:09887
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Leads Biolabs Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nanjing Leads Biolabs Co's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-233.56/195.818
=-119.27 %

Nanjing Leads Biolabs Co's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-49.741/195.818
=-25.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -25.40% mean?
Nanjing Leads Biolabs Co (HKSE:09887) has a Net Margin % of -25.40% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Nanjing Leads Biolabs Co and its competitors. According to the industry distribution chart, Nanjing Leads Biolabs Co ranks #512 out of 944 companies in the Biotechnology industry, placing it in the top 54.2%.
Is Nanjing Leads Biolabs Co's Net Margin % too high?
Nanjing Leads Biolabs Co's current Net Margin % is -25.40%. Based on the distribution chart, Nanjing Leads Biolabs Co ranks #512 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nanjing Leads Biolabs Co ranks #512 out of 944 companies for Net Margin %. This places Nanjing Leads Biolabs Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current Net Margin % is -25.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (HKSE:09887) has a current Net Margin % of -25.40%. The current Net Margin % is -25.40%. Nanjing Leads Biolabs Co's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (HKSE:09887), the current Net Margin % is -25.40% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanjing Leads Biolabs Co Business Description

Other Exchanges 0DX:Germany
Address Jialingjiang Street, 18E, Floor 8, Building 03, Jiangsu Province, Nanjing, CHN, 210019
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
10GF Score

Get the complete analysis for HKSE:09887

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$74.60
Price